BioAffinity Technologies, Inc.: announced sponsorship of a CHEST 2026 presentation

What happened BioAffinity Technologies, Inc. announced on Oct 15, 2026 that it will sponsor a Learning Theater presentation at CHEST 2026, the annual meeting of the American College of Chest Physicians. The filing says the presentation will cover the evolving role of CyPath Lung® in improving lung cancer risk stratification and managing pulmonary nodules in patients at high risk for lung cancer, and will include discussion of the company’s positive research data in the development of a new test measuring asthma and COPD-related lung inflammation and drug-related receptors.

Key details

• Date announced: Oct 15, 2026.
• Event: Learning Theater presentation at CHEST 2026 (annual meeting of the American College of Chest Physicians).
• Topics named in the filing: CyPath Lung® for lung cancer risk stratification and management of pulmonary nodules; new test for asthma and COPD-related lung inflammation and drug-related receptors.
• The filing states a press release was issued announcing the sponsorship.

Why it may matter

• Item reported: Item 8.01 (Other events). Item 8.01 covers other events the company deems of interest to investors, including this sponsorship and the described research topics.
• This filing does not show why the insider traded or why the company acted.